Türkİye, Health, Latest on coronavirus outbreak

‘Turkey 3rd country worldwide with vaccines at clinical phase'

Turkey will continue investing in vaccine efforts to undertake key role in world, says President Erdogan

Sena Guler   | 28.01.2021
‘Turkey 3rd country worldwide with vaccines at clinical phase'


Joining just two other vaccines in the world, vaccines developed in Turkey are now set to enter the clinical study phase, said the nation’s president on Thursday.

“Three innovative [Turkish] vaccine candidates are on the verge of starting phase studies. Work by our professors has the potential to become the third vaccine candidate in the clinical stage in its category in the world,” Recep Tayyip Erdogan told an award ceremony for the Scientific and Technological Research Council of Turkey (TUBITAK) and Turkish Academy of Sciences (TUBA) in the capital Ankara.

According to the World Health Organization, Turkey has the third-largest number of COVID-19 vaccine projects in the world, behind only the US and China, Erdogan said.

“We have launched a science campaign with the TUBITAK COVID-19 Turkey Platform. In this platform, 436 researchers are carrying out 17 projects on vaccine and drug development,” he added.

Noting that Turkey’s investments in the field are not limited to the pandemic era, Erdogan said Turkey is looking to become a key player in the international arena by developing and producing its own vaccines.

Stages of vaccine development studies

Vaccine development studies are conducted in four stages, from the pre-clinical stage to Phase 1, Phase 2, and Phase 3.

In pre-clinical studies, candidate jabs are tested on animals to determine their reliability and effectiveness.

During this phase, candidates are tested for side effects and whether they produce sufficient antibodies.

The vaccine is then tested on humans in Phase 1, Phase 2, and Phase 3.

Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
Related topics
Bu haberi paylaşın